Eravacycline: a review in complicated intra-abdominal infections

LJ Scott - Drugs, 2019 - Springer
Eravacycline (Xerava™), a novel fully synthetic fluorocycline, consists of the tetracyclic core
scaffold with unique modifications in the tetracyclic D ring; consequently, it exhibits potent in …

Eravacycline, a newly approved fluorocycline

YR Lee, CE Burton - European Journal of Clinical Microbiology & …, 2019 - Springer
Complicated intra-abdominal infections (cIAIs) are commonly associated with
multimicroorganisms and treatment choices are becoming narrower due to developing …

In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017

I Morrissey, M Olesky, S Hawser, SH Lob… - Antimicrobial agents …, 2020 - Am Soc Microbiol
Eravacycline is a novel, fully synthetic fluorocycline antibiotic developed for the treatment of
serious infections, including those caused by multidrug-resistant (MDR) pathogens. Here …

Multimodal nanoimmunotherapy engages neutrophils to eliminate Staphylococcus aureus infections

J Zhu, R Xie, R Gao, Y Zhao, N Yodsanit, M Zhu… - Nature …, 2024 - nature.com
The increasing prevalence of antimicrobial resistance in Staphylococcus aureus
necessitates alternative therapeutic approaches. Neutrophils play a crucial role in the fight …

Current and future treatment options for community-associated MRSA infection

A Khan, B Wilson, IM Gould - Expert Opinion on Pharmacotherapy, 2018 - Taylor & Francis
ABSTRACT Introduction: Community-associated MRSA (CA-MRSA) represents a global
epidemic which beautifully encapsulates the fascinating ability of bacterial organisms to …

Evaluation of eravacycline: a novel fluorocycline

S Alosaimy, JC Abdul‐Mutakabbir… - … : The Journal of …, 2020 - Wiley Online Library
Eravacycline (ERV), formerly known as TP‐434, is a novel tetracycline (TET) antibiotic that
exhibits in vitro activity against various gram‐positive, gram‐negative aerobic and anaerobic …

In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD …

GG Zhanel, MR Baxter, HJ Adam, J Sutcliffe… - … and infectious disease, 2018 - Elsevier
Abstract Gram-negative (n= 2213) and Gram-positive (n= 2424) pathogens isolated from
patients in 13 Canadian hospitals in 2014 and 2015 were tested for in vitro susceptibility to …

Epidemiology and risk factors of rectal colonization of carbapenemase-producing Enterobacteriaceae among high-risk patients from ICU and HSCT wards in a …

L Yan, J Sun, X Xu, S Huang - Antimicrobial Resistance & Infection Control, 2020 - Springer
Abstract Background Nosocomial carbapenemase-producing Enterobacterieceae (CPE)
infections constitute a major global health concern and are associated with increased …

CP-CRE/non-CP-CRE stratification and CRE resistance mechanism determination help in better managing CRE bacteremia using ceftazidime–avibactam and …

H Zou, SJ Xiong, QX Lin, ML Wu, SQ Niu… - Infection and drug …, 2019 - Taylor & Francis
Purpose This observational study aimed to identify the independent risk factors for both the
acquisition and mortality of carbapenemase-producing carbapenem-resistant …

Integrative analysis of outer membrane vesicles proteomics and whole-cell transcriptome analysis of eravacycline induced Acinetobacter baumannii strains

DK Kesavan, A Vasudevan, L Wu, J Chen, Z Su… - BMC microbiology, 2020 - Springer
Background Acinetobacter baumannii is a multidrug-resistant (MDR) hazardous bacterium
with very high antimicrobial resistance profiles. Outer membrane vesicles (OMVs) help …